These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29271100)

  • 1. Managing opioid overdose in pregnancy with take-home naloxone.
    Blandthorn J; Bowman E; Leung L; Bonomo Y; Dietze P
    Aust N Z J Obstet Gynaecol; 2018 Aug; 58(4):460-462. PubMed ID: 29271100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods.
    Ashrafioun L; Gamble S; Herrmann M; Baciewicz G
    Subst Abus; 2016; 37(1):76-81. PubMed ID: 26514071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ensure global access to naloxone for opioid overdose management.
    Balster RL; Walsh SL
    Addiction; 2016 Apr; 111(4):589-90. PubMed ID: 26995171
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of opioid overdose: a brief review of naloxone pharmacology and delivery.
    Hendley TM; Hersh EV; Moore PA; Stahl B; Saraghi M
    Gen Dent; 2017; 65(3):18-21. PubMed ID: 28475079
    [No Abstract]   [Full Text] [Related]  

  • 6. Intranasal naloxone soon to become part of evolving clinical practice around opioid overdose prevention.
    Dietze P; Cantwell K
    Addiction; 2016 Apr; 111(4):584-6. PubMed ID: 26995168
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergency department naloxone distribution: a Rhode Island department of health, recovery community, and emergency department partnership to reduce opioid overdose deaths.
    Samuels E
    R I Med J (2013); 2014 Oct; 97(10):38-9. PubMed ID: 25271659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addiction stigma and the production of impediments to take-home naloxone uptake.
    Fomiatti R; Farrugia A; Fraser S; Dwyer R; Neale J; Strang J
    Health (London); 2022 Mar; 26(2):139-161. PubMed ID: 32529843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of naloxone for overdose prevention to chronic pain patients.
    Coe MA; Walsh SL
    Prev Med; 2015 Nov; 80():41-3. PubMed ID: 26024850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-Based Guidelines for EMS Administration of Naloxone.
    Williams K; Lang ES; Panchal AR; Gasper JJ; Taillac P; Gouda J; Lyng JW; Goodloe JM; Hedges M
    Prehosp Emerg Care; 2019; 23(6):749-763. PubMed ID: 30924736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program.
    Chronister KJ; Lintzeris N; Jackson A; Ivan M; Dietze PM; Lenton S; Kearley J; van Beek I
    Drug Alcohol Rev; 2018 May; 37(4):464-471. PubMed ID: 27071354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of Pediatric Opioid Toxicity with Take-Home Naloxone: a Case Report.
    Lebin JA; Chen BC; Valento MJ
    J Med Toxicol; 2019 Apr; 15(2):134-135. PubMed ID: 30632074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australia reschedules naloxone for opioid overdose.
    Lenton SR; Dietze PM; Jauncey M
    Med J Aust; 2016 Mar; 204(4):146-7. PubMed ID: 26937664
    [No Abstract]   [Full Text] [Related]  

  • 17. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
    Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
    Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and deaths.
    Rich JD; Green TC; McKenzie MS
    N Engl J Med; 2011 Feb; 364(7):686. PubMed ID: 21323559
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethical issues and stakeholders matter.
    Dale O
    Addiction; 2016 Apr; 111(4):587-9. PubMed ID: 26995170
    [No Abstract]   [Full Text] [Related]  

  • 20. Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs.
    Dietze PM; Draper B; Olsen A; Chronister KJ; van Beek I; Lintzeris N; Dwyer R; Nelson M; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):472-479. PubMed ID: 29473245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.